Supporting this approach, a recent study demonstrated that once-weekly treatment with dulaglutide significantly improved glycemic control over 26 weeks compared to placebo in youth with T2DM already receiving metformin and/or insulin therapy [52]. This evidence concerns the gene INS and type 2 diabetes mellitus.